SENS · Insider Trading
Senseonics Holdings, Inc. Common Stock
Every open-market purchase and sale reported by SENS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-05 | Edward Fiorentino | Director | A | +1,418 | +$14.12K |
| 2026-10-05 | Edelman Steven | Director | A | +1,292 | +$12.87K |
| 2026-10-05 | Douglas S Prince | Director | A | +815 | +$8.12K |
| 2026-10-05 | Douglas A Roeder | Director | A | +1,480 | +$14.74K |
| 2026-08-20 | Douglas A Roeder | Director | Buy | +13,953 | +$125.30K |
| 2026-07-02 | Edelman Steven | Director | A | +2,402 | +$12.87K |
| 2026-07-02 | Douglas A Roeder | Director | A | +2,751 | +$14.75K |
| 2026-07-02 | Douglas S Prince | Director | A | +1,515 | +$8.12K |
| 2026-07-02 | Edward Fiorentino | Director | A | +2,635 | +$14.12K |
| 2026-06-17 | Frederick T. Sullivan | Chief Financial Officer | F | −5,397 | −$38.75K |
| 2026-06-17 | Kenneth L Horton | GC & Corp. Development Advisor | F | −9,545 | −$68.53K |
| 2026-06-17 | Francine Kaufman | Chief Medical Officer | F | −4,010 | −$28.79K |
| 2026-06-17 | Mukul JAIN | Chief Operating Officer | F | −16,194 | −$116.27K |
| 2026-06-17 | Timothy T Goodnow | President and CEO | F | −32,598 | −$234.05K |
| 2026-06-17 | Brian B Hansen | Chief Commercial Officer | F | −5,420 | −$38.92K |
| 2026-05-21 | Douglas A Roeder | Director | A | +9,852 | — |
| 2026-05-21 | Stephen P DeFalco | Director | A | +9,852 | — |
| 2026-05-21 | Edelman Steven | Director | A | +9,852 | — |
| 2026-05-21 | Brian B Hansen | Chief Commercial Officer | A | +90,253 | — |
| 2026-05-21 | Mukul JAIN | Chief Operating Officer | A | +270,759 | — |
| 2026-05-21 | Douglas S Prince | Director | A | +9,852 | — |
| 2026-05-21 | Kenneth L Horton | GC & Corp. Development Advisor | A | +157,943 | — |
| 2026-05-21 | Sharon Larkin | Director | A | +9,852 | — |
| 2026-05-21 | Frederick T. Sullivan | Chief Financial Officer | A | +90,253 | — |
| 2026-05-21 | Edward Fiorentino | Director | A | +9,852 | — |
| 2026-05-21 | Francine Kaufman | Chief Medical Officer | A | +63,177 | — |
| 2026-05-21 | Timothy T Goodnow | President and CEO | A | +553,701 | — |
| 2026-05-18 | Kenneth L Horton | GC & Corp. Development Advisor | F | −7,320 | −$42.60K |
| 2026-05-18 | Timothy T Goodnow | President and CEO | F | −28,598 | −$166.44K |
| 2026-05-18 | Mukul JAIN | Chief Operating Officer | F | −13,681 | −$79.62K |
| 2026-05-18 | Francine Kaufman | Chief Medical Officer | F | −6,058 | −$35.26K |
| 2026-05-18 | Frederick T. Sullivan | Chief Financial Officer | F | −9,005 | −$52.41K |
| 2026-05-13 | Douglas A Roeder | Director | Buy | +22,686 | +$126.13K |
| 2026-04-02 | Edward Fiorentino | Director | A | +2,124 | +$14.12K |
| 2026-04-02 | Douglas A Roeder | Director | A | +2,218 | +$14.75K |
| 2026-04-02 | Douglas S Prince | Director | A | +1,221 | +$8.12K |
| 2026-04-02 | Edelman Steven | Director | A | +1,936 | +$12.87K |
| 2026-03-16 | Timothy T Goodnow | President and CEO | Buy | +17,225 | +$99.73K |
| 2026-03-16 | Douglas A Roeder | Director | Buy | +17,500 | +$100.28K |
| 2026-01-05 | Douglas S Prince | Director | A | +1,379 | +$8.12K |
| 2026-01-05 | Douglas A Roeder | Director | A | +2,504 | +$14.75K |
| 2026-01-05 | Edward Fiorentino | Director | A | +2,398 | +$14.12K |
| 2026-01-05 | Edelman Steven | Director | A | +2,185 | +$12.87K |
| 2025-11-18 | Timothy T Goodnow | President and CEO | F | −27,067 | −$169.44K |
| 2025-11-18 | Kenneth L Horton | GC & Corp. Development Advisor | F | −5,997 | −$37.54K |
| 2025-11-18 | Frederick T. Sullivan | Chief Financial Officer | F | −6,402 | −$40.08K |
| 2025-11-18 | Francine Kaufman | Chief Medical Officer | F | −4,605 | −$28.83K |
| 2025-11-18 | Mukul JAIN | Chief Operating Officer | F | −10,317 | −$64.58K |
| 2025-11-13 | Edelman Steven | Director | Buy | +10,000 | +$65.50K |
| 2025-11-10 | Douglas A Roeder | Director | Buy | +15,000 | +$87.45K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Timothy T Goodnow | President and CEO | 1,143,748 | $9.70M |
| Mukul JAIN | Chief Operating Officer | 500,863 | $4.25M |
| Kenneth L Horton | GC & Corp. Development Advisor | 285,512 | $2.42M |
| Frederick T. Sullivan | Chief Financial Officer | 226,477 | $1.92M |
| Francine Kaufman | Chief Medical Officer | 177,057 | $1.50M |
| Douglas A Roeder | Director | 172,671 | $1.46M |
| Brian B Hansen | Chief Commercial Officer | 126,937 | $1.08M |
| Stephen P DeFalco | Director | 111,019 | $941.44K |
| Edelman Steven | Director | 92,375 | $783.34K |
| Edward Fiorentino | Director | 87,392 | $741.08K |
| Douglas S Prince | Director | 70,146 | $594.84K |
| Sharon Larkin | Director | 41,862 | $354.99K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SENS quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.